Several studies have shown that loss of Afadin expression leads to enhanced cell invasion in diverse cancer types, including breast, colorectal, endometrial, and pancreatic cancer (Fournier et al. 2011; Sun et al. 2014; Xu et al. 2015; Yamamoto et al. 2015). Here, AFDN is linked to familial pancreatic carcinoma.